Roche invests 120 million Swiss francs in new production facilities at Basel
Basel, 19 May 2014
Today Roche announced plans to invest a total of 120 million Swiss francs in the construction of new production facilities in Building 50, an existing building at its Basel site. Eighty five million francs will go into a new facility for chemically manufactured medicines, while the remaining 35 million francs will be invested in the expansion and refitting of an existing multipurpose unit for the production of investigational drugs and medicines that are already on the market.
Matthias M. Baltisberger, Head of Basel/Kaiseraugst Site, commented: "This investment is an important step for our future. In developing these two new facilities, we are enhancing the site's appeal and continuing to provide jobs for highly skilled technicians, scientists, engineers and quality specialists."
Initial preparatory work has already started in Building 50. Production of the highly effective medicines is scheduled to start in the third quarter of 2016, while the flexible multipurpose unit, which can be rapidly adapted to changing production requirements, will enter service in June 2015.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.